

IARC Monographs on the Identification of Carcinogenic Hazards to Humans

Volume 142: Butyl benzyl phthalate, Dibutyl phthalate, and Diisononyl phthalate

Lyon, France: 9–16 June 2026

PRELIMINARY LIST OF PARTICIPANTS

IARC requests that Meeting Observers and others outside the Working Group do not contact or lobby Working Group Members, send them written materials, or offer favours that could appear to be linked to their participation. (You may send pertinent written materials to IARC.) IARC will ask participants to report all such contacts and will publicly reveal any attempt to influence the meeting. Thank you for your cooperation.

Working Group Members serve in their individual capacities as scientists and not as representatives of their government or any organization with which they are affiliated. Affiliations are provided for identification purposes only.

Members

Etienne Blanc, Université de Rennes and Institut de recherche en santé, environnement et travail (IRSET), France

Myriam Borgatta, Center for Primary Care and Public Health, University of Lausanne, Switzerland

Diana Ceballos, Department of Environmental & Occupational Health Sciences, University of Washington, USA

Nathan DeBono, Dalla Lana School of Public Health, University of Toronto, Canada

Radu-Corneliu Duca, Luxembourg Health Directorate, Ministry of Health and Social Security, Luxembourg

Deborah Glass, Centre for Occupational and Environmental Health, Monash University, Australia

David Josephy, Department of Molecular and Cellular Biology, University of Guelph, Canada

Kurunthachalam Kannan, Wadsworth Center, New York State Department of Health, USA

Abderrezak Khelfi, University of Algiers 1, National Center of Toxicology, Algeria

Marike Kolossa-Gehring, Ruhr University Bochum Medical Faculty, Institute of the Ruhr University Bochum (IPA), Germany

Allison Kupsco, Mailman School of Public Health, Columbia University, USA

Lizbeth López-Carillo, Instituto Nacional de Salud Pública, Mexico

Francesca Mancini, Université Paris-Saclay and Institut national de la santé et de la recherche médicale (INSERM), France

Kumiko Ogawa, Department of Toxicology, Hoshi University, Japan

Claire Philippat, Institut national de la santé et de la recherche médicale (INSERM), France


Kátia Pinello, Institute of Public Health (ISPUP), University of Porto, Portugal

Katherine Reeves, School of Public Health & Health Sciences, University of Massachusetts Amherst, USA

Jennifer Schlezinger, School of Public Health, University of Boston, USA

Meng Sun, Office of Environmental Health Hazard Assessment, California Environmental Protection Agency, USA

Cecilia Williams, Department of Medicine, Karolinska Institute, Sweden



Marcin Wojewodzic, Norwegian Institute of Public Health, Norway
Luoping Zhang, School of Public Health, University of California at Berkeley, USA
Johanna Zilliacus, Institute of Environmental Medicine, Karolinska Institute, Sweden

Invited Specialists

None

Representatives of national and international health agencies

None

Observers

Amanda Buerger, ToxStrategies, USA¹
Nadine Engel, Evonik Oxeno GmbH, Germany²
Hesbon Nyambego, ExxonMobil Biomedical Sciences Inc, USA³
Nigel Sarginson, Sarginson Consulting SRL, Belgium⁴

IARC Secretariat


Lamia Benbrahim-Tallaa, *IARC Monographs Programme*
Aline de Conti, *IARC Monographs Programme*
Caterina Facchin, *IARC Monographs Programme*
Andrew Kunzmann, *IARC Monographs Programme*
Oliver Langselius, Cancer Surveillance Branch
Federica Madia, *IARC Monographs Programme* (Responsible Officer)
Heidi Mattock, *IARC Monographs Programme*
Elisa Pasqual, *IARC Monographs Programme*
Mario Postiglione, Nutrition and Metabolism Branch
Mary Schubauer-Berigan, *IARC Monographs Programme* (Programme Head)

¹ Dr Buerger is employed by ToxStrategies, a consulting company operating in the life sciences and chemicals safety domain, where she is conducting research funded (in an undisclosed amount) by the American Chemistry Council (ACC) and ExxonMobil Biomedical Sciences, Inc, on topics related to this meeting. Her travel costs to attend the meeting were paid by the ACC High Phthalates Panel. She was formerly employed by Stantec ChemRisk, a consulting company that assisted in preparation of Premarket Tobacco Product Applications (PMTAs) to the US Food and Drug Administration.

² Dr Engel is employed by Evonik Oxeno GmbH & Co. KG, a company manufacturing and marketing C4 chemical products. She is Chair of the Scientific Working Group within the European Plasticisers, a trade association of chemical companies producing plasticizers. She is representing European Plasticisers and VinylPlus®, a polyvinyl chloride manufacturers' trade association, at this meeting. Her travel costs are being paid by European Plasticisers.

³ Dr Nyambego is employed (and his travel costs to attend the meeting were paid) by ExxonMobil Biomedical Sciences Inc, a research organisation within the ExxonMobil group. He receives research support for his employer on the topic of diisononyl phthalate.

⁴ Dr Sarginson is the Director of Sarginson Consulting SRL, an independent consulting company. He was formerly employed by ExxonMobil and reports ongoing work as a consultant to Burson, a lobbying organisation in the field of EU governmental affairs, on the topic of diisononyl phthalate. He formerly acted as Chair of European Plasticisers.



Eero Suonio, *IARC Monographs Programme*
Fanélie Vasson, Nutrition and Metabolism Branch
Sara Veneziano, Nutrition and Metabolism Branch
Susana Viegas, *IARC Monographs Programme*
Roland Wedekind, *IARC Monographs Programme*
Jiri Zavadil, Environment and Lifestyle Epidemiology Branch

NOTE REGARDING CONFLICTS OF INTERESTS: Each participant first received a preliminary invitation with the request to complete and sign the IARC/WHO Declaration of Interests, which covers employment and consulting activities, individual and institutional research support, and other financial or non-financial interests (e.g. public statements and positions related to the subject of the meeting).

Official invitations were extended after careful assessment of any declared interests that might constitute a conflict of interest. Pertinent and significant conflicts are disclosed here. Information about other potential conflicts that are not disclosed may be sent to the Head of the *IARC Monographs* programme at imo@iarc.who.int.

Participants identified as Invited Specialists will not serve as meeting chair or subgroup chair, draft text that pertains to the description or interpretation of cancer data, or participate in the evaluations. The Declarations will be updated and reviewed again at the opening of the meeting.

Posted on 29 April 2026